PE20211114A1 - Metodos y composiciones para terapia con celulas oculares - Google Patents
Metodos y composiciones para terapia con celulas ocularesInfo
- Publication number
- PE20211114A1 PE20211114A1 PE2021000558A PE2021000558A PE20211114A1 PE 20211114 A1 PE20211114 A1 PE 20211114A1 PE 2021000558 A PE2021000558 A PE 2021000558A PE 2021000558 A PE2021000558 A PE 2021000558A PE 20211114 A1 PE20211114 A1 PE 20211114A1
- Authority
- PE
- Peru
- Prior art keywords
- limbar
- modified
- reduced
- stem cell
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UNA CELULA MADRE LIMBAR MODIFICADA, QUE HA REDUCIDO O ELIMINADO LA EXPRESION DE BETA-2-MICROGLOBULINA (B2M) EN RELACION CON UNA CELULA MADRE LIMBAR NO MODIFICADA, EN DONDE LA EXPRESION DE B2M SE REDUCE O ELIMINA POR UN SISTEMA CRISPR QUE COMPRENDE UNA MOLECULA DE ARNg QUE COMPRENDE UN DOMINIO DE DIRECCIONAMIENTO COMPLEMENTARIO A UNA SECUENCIA DIANA EN EL GEN B2M, EN DONDE LA REGION DIANA DE LA MOLECULA DE ARNg PARA B2M COMPRENDE UN DOMINIO DE DIRECCIONAMIENTO QUE COMPRENDE LA SECUENCIA DE CUALQUIERA DE LAS SEQ ID NOs: 23-105 O 108-119 O 134-140. TAMBIEN SE REFIERE A UN METODO DE PREPARACION DE UNA CELULA MADRE LIMBAR MODIFICADA O POBLACION DE CELULAS MADRE LIMBARES MODIFICADAS, Y A UNA COMPOSICION QUE COMPRENDE LAS MISMAS, LA CUAL ES UTIL EN EL TRATAMIENTO DE UNA ENFERMEDAD OCULAR TAL COMO DEFICIENCIA DE CELULAS MADRE LIMBARES.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862750962P | 2018-10-26 | 2018-10-26 | |
US201962902639P | 2019-09-19 | 2019-09-19 | |
PCT/IB2019/059162 WO2020084580A1 (en) | 2018-10-26 | 2019-10-25 | Methods and compositions for ocular cell therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211114A1 true PE20211114A1 (es) | 2021-06-22 |
Family
ID=68393038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000558A PE20211114A1 (es) | 2018-10-26 | 2019-10-25 | Metodos y composiciones para terapia con celulas oculares |
Country Status (22)
Country | Link |
---|---|
US (1) | US20200131474A1 (es) |
EP (1) | EP3870289A1 (es) |
JP (1) | JP2022505658A (es) |
KR (1) | KR20210069075A (es) |
CN (1) | CN112969472A (es) |
AU (1) | AU2019365590A1 (es) |
BR (1) | BR112021007628A2 (es) |
CA (1) | CA3116512A1 (es) |
CL (1) | CL2021001034A1 (es) |
CO (1) | CO2021005289A2 (es) |
CR (1) | CR20210196A (es) |
CU (1) | CU20210033A7 (es) |
EC (1) | ECSP21028556A (es) |
IL (1) | IL282447A (es) |
JO (1) | JOP20210080A1 (es) |
MX (1) | MX2021004532A (es) |
PE (1) | PE20211114A1 (es) |
PH (1) | PH12021550761A1 (es) |
SG (1) | SG11202102615RA (es) |
TW (1) | TW202030324A (es) |
UY (1) | UY38427A (es) |
WO (1) | WO2020084580A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2019133280A (ru) | 2017-03-22 | 2021-04-22 | Новартис Аг | Композиции и способы для иммуноонкологии |
JOP20190257A1 (ar) * | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
EP4069303A4 (en) * | 2019-12-03 | 2023-11-29 | The Schepens Eye Research Institute, Inc. | INJECTABLE HYDROGELES FOR CELL DELIVERANCE TO THE VIRTUAL BODY |
WO2021220132A1 (en) * | 2020-04-27 | 2021-11-04 | Novartis Ag | Methods and compositions for ocular cell therapy |
CA3217356A1 (en) * | 2021-04-20 | 2022-10-27 | Walking Fish Therapeutics, Inc. | Engineering b cell-based protein factories to treat serious diseases |
WO2023028348A1 (en) * | 2021-08-27 | 2023-03-02 | Metagenomi, Inc. | Enzymes with ruvc domains |
CN116286905B (zh) * | 2023-05-11 | 2023-08-15 | 内蒙古大学 | 牛源化CRISPR/boCas9基因编辑系统、方法及应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2770497B2 (ja) | 1988-11-24 | 1998-07-02 | 吉富製薬株式会社 | トランス―4―アミノ(アルキル)―1―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途 |
KR0133372B1 (ko) | 1991-09-06 | 1998-04-23 | 고야 다다시 | 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도 |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US5989835A (en) | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
CZ301044B6 (cs) | 1996-08-12 | 2009-10-21 | Mitsubishi Tanabe Pharma | Léciva obsahující amidové deriváty inhibující Rho kinázu |
JPH11130751A (ja) | 1997-10-30 | 1999-05-18 | Yoshitomi Pharmaceut Ind Ltd | アミド化合物およびそれらの酸付加塩の標識化合物 |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
JP4851003B2 (ja) | 2000-12-21 | 2012-01-11 | 田辺三菱製薬株式会社 | 肝臓障害に基づく疾患の予防・治療剤 |
PE20021011A1 (es) | 2001-03-23 | 2003-02-01 | Bayer Corp | Derivados quinazolinicos como inhibidores de la rho-quinasa |
WO2002085909A1 (en) | 2001-04-20 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | INHIBITORS OF RHO KINASE |
US6642263B2 (en) | 2001-11-19 | 2003-11-04 | Iconix Pharmaceuticals Inc. | Modulators of Rho C activity |
EP1465900B1 (en) | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitors |
US6943172B2 (en) | 2002-01-23 | 2005-09-13 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
JP4469179B2 (ja) | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Rhoキナーゼ阻害剤としてのピリミジン誘導体 |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
WO2003082808A1 (fr) | 2002-04-03 | 2003-10-09 | Sumitomo Pharmaceuticals Company, Limited. | Derives de benzamide |
EP1562935B1 (de) | 2002-10-28 | 2006-09-06 | Bayer HealthCare AG | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
JP4869068B2 (ja) | 2003-06-19 | 2012-02-01 | スミスクライン ビーチャム コーポレーション | 化合物 |
WO2005003101A2 (en) | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Pyrazine and pyridine derivatives as rho kinase inhibitors |
CN1242058C (zh) * | 2004-04-09 | 2006-02-15 | 西北农林科技大学 | 表皮干细胞构建组织工程化角膜上皮植片的制备方法及其用途 |
DK3401400T3 (da) | 2012-05-25 | 2019-06-03 | Univ California | Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering |
US11685935B2 (en) | 2013-05-29 | 2023-06-27 | Cellectis | Compact scaffold of Cas9 in the type II CRISPR system |
US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
CA2953524A1 (en) * | 2014-06-27 | 2015-12-30 | The Regents Of The University Of California | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof |
EP3169776A4 (en) | 2014-07-14 | 2018-07-04 | The Regents of The University of California | Crispr/cas transcriptional modulation |
US20180141992A1 (en) * | 2014-11-06 | 2018-05-24 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
JP2018515139A (ja) * | 2015-05-08 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 万能ドナー幹細胞および関連する方法 |
MX2018006767A (es) * | 2015-12-04 | 2019-03-14 | Novartis Ag | Composiciones y metodos para oncologia inmunologica. |
EP3390437A4 (en) | 2015-12-18 | 2019-10-16 | Sangamo Therapeutics, Inc. | TARGETED DISORDER OF MHC CELL RECEPTOR |
WO2017143210A1 (en) | 2016-02-19 | 2017-08-24 | The General Hospital Corporation | Methods for generating universal and custom mhc/hla-compatible hematopoietic progenitor cells |
EP3469362A1 (en) | 2016-06-10 | 2019-04-17 | Gadeta B.V. | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof |
JP2019532640A (ja) | 2016-09-29 | 2019-11-14 | ナントクエスト インコーポレイテッド | 免疫原性が低下したhlaクラスi欠損nk−92細胞 |
WO2018132783A1 (en) * | 2017-01-13 | 2018-07-19 | The Regents Of The University Of California | Immunoengineered pluripotent cells |
JOP20190257A1 (ar) * | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
CN115671398B (zh) * | 2022-11-22 | 2024-03-01 | 首都医科大学附属北京同仁医院 | 一种3d打印仿生角膜缘移植物及其制备方法和用途 |
-
2019
- 2019-10-23 UY UY0001038427A patent/UY38427A/es not_active Application Discontinuation
- 2019-10-24 TW TW108138491A patent/TW202030324A/zh unknown
- 2019-10-25 EP EP19795669.1A patent/EP3870289A1/en not_active Withdrawn
- 2019-10-25 US US16/663,722 patent/US20200131474A1/en not_active Abandoned
- 2019-10-25 KR KR1020217012812A patent/KR20210069075A/ko not_active Application Discontinuation
- 2019-10-25 CR CR20210196A patent/CR20210196A/es unknown
- 2019-10-25 CA CA3116512A patent/CA3116512A1/en active Pending
- 2019-10-25 AU AU2019365590A patent/AU2019365590A1/en not_active Abandoned
- 2019-10-25 PE PE2021000558A patent/PE20211114A1/es unknown
- 2019-10-25 CU CU2021000033A patent/CU20210033A7/es unknown
- 2019-10-25 JP JP2021522072A patent/JP2022505658A/ja active Pending
- 2019-10-25 MX MX2021004532A patent/MX2021004532A/es unknown
- 2019-10-25 WO PCT/IB2019/059162 patent/WO2020084580A1/en unknown
- 2019-10-25 CN CN201980069687.5A patent/CN112969472A/zh active Pending
- 2019-10-25 BR BR112021007628-0A patent/BR112021007628A2/pt unknown
- 2019-10-25 SG SG11202102615RA patent/SG11202102615RA/en unknown
- 2019-10-25 JO JOP/2021/0080A patent/JOP20210080A1/ar unknown
-
2021
- 2021-04-06 PH PH12021550761A patent/PH12021550761A1/en unknown
- 2021-04-19 IL IL282447A patent/IL282447A/en unknown
- 2021-04-22 CL CL2021001034A patent/CL2021001034A1/es unknown
- 2021-04-22 EC ECSENADI202128556A patent/ECSP21028556A/es unknown
- 2021-04-23 CO CONC2021/0005289A patent/CO2021005289A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021007628A2 (pt) | 2021-10-13 |
UY38427A (es) | 2020-05-29 |
JOP20210080A1 (ar) | 2023-01-30 |
IL282447A (en) | 2021-06-30 |
CA3116512A1 (en) | 2020-04-30 |
MX2021004532A (es) | 2021-07-16 |
ECSP21028556A (es) | 2021-05-31 |
SG11202102615RA (en) | 2021-05-28 |
CU20210033A7 (es) | 2021-12-08 |
KR20210069075A (ko) | 2021-06-10 |
EP3870289A1 (en) | 2021-09-01 |
CN112969472A (zh) | 2021-06-15 |
CO2021005289A2 (es) | 2021-05-10 |
US20200131474A1 (en) | 2020-04-30 |
WO2020084580A1 (en) | 2020-04-30 |
CR20210196A (es) | 2021-07-27 |
PH12021550761A1 (en) | 2021-12-13 |
AU2019365590A1 (en) | 2021-04-22 |
JP2022505658A (ja) | 2022-01-14 |
TW202030324A (zh) | 2020-08-16 |
CL2021001034A1 (es) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211114A1 (es) | Metodos y composiciones para terapia con celulas oculares | |
WO2019126634A3 (en) | Targeted integration of nucleic acids | |
PH12020500231A1 (en) | Interleukin-21 muteins and methods of treatment | |
EA200801074A1 (ru) | Способы получения искусственных гибридных семян | |
PH12018500965A1 (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
EA201991255A1 (ru) | Регулируемая транскрипция | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
BR112021023571A2 (pt) | Enxerto de emplastro de células-tronco / progenitores em órgãos sólidos | |
EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
EP4219747A3 (en) | Method of preparing sterilized compositions for stabilization of extracellular nucleic acids | |
PE20110358A1 (es) | Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias | |
PE20140867A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso | |
EA201891629A1 (ru) | Способы и композиции для повышения эффективности нацеленной модификации генов с применением опосредуемой олигонуклеотидами репарации генов | |
EA202092489A1 (ru) | СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ | |
MX2021012041A (es) | Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas. | |
PE20210463A1 (es) | Uso de composiciones que contienen streptomyces melanosporofaciens agl225 en el control de enfermedades de las plantas | |
CL2019003248A1 (es) | Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria. | |
PE20170147A1 (es) | Composiciones de oligonucleotidos y metodos para realizarlas | |
PH12020551642A1 (en) | Aav compositions, methods of making and methods of use | |
AU2017245117A1 (en) | Method for introducing substance into plant | |
BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
BR112017009515A8 (pt) | Fitase, método para obter a mesma e uso do mesmo | |
WO2018155925A3 (ko) | 하이드로겔 중합체를 이용한 탈세포화 조직의 제조방법 및 이로부터 제조된 탈세포화 조직 | |
EA202192893A1 (ru) | Среда для культивирования эукариотических клеток | |
AU2020302077A8 (en) | Compositions and methods for treatment of fungal infections |